Genes, Vol. 10, Pages 599: Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
In conclusion, we discuss the challenges of integrating prostate cancer pharmacogenomic biomarkers into the clinic and the strategies that can be employed to allow a more comprehensive, evidence-based approach to facilitate their clinical integration. Expanding the integration of pharmacogenetic markers in prostate cancer treatment procedures will enhance precision medicine and ultimately improve patient outcomes.
Source: Genes - Category: Genetics & Stem Cells Authors: Reka Varnai Leena M. Koskinen Laura E. M äntylä Istvan Szabo Liesel M. FitzGerald Csilla Sipeky Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Genetics | Prostate Cancer | Study | Taxotere | Toxicology